<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05024032</url>
  </required_header>
  <id_info>
    <org_study_id>17507</org_study_id>
    <secondary_id>I8F-MC-GPIA</secondary_id>
    <nct_id>NCT05024032</nct_id>
  </id_info>
  <brief_title>A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)</brief_title>
  <acronym>SURMOUNT-CN</acronym>
  <official_title>Efficacy and Safety of Tirzepatide Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-CN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of tirzepatide in Chinese participants without Type 2 Diabetes who have&#xD;
      obesity or overweight.&#xD;
&#xD;
      The main purpose is to learn more about how tirzepatide affects body weight.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 16, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent Change from Randomization in Body Weight</measure>
    <time_frame>Randomization, Week 52</time_frame>
    <description>Mean Percent Change from Randomization in Body Weight</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants who Achieve ≥5% Body Weight Reduction</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of Participants who Achieve ≥5% Body Weight Reduction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Body Weight</measure>
    <time_frame>Randomization, Week 20</time_frame>
    <description>Mean Change from Randomization in Body Weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve ≥10% Body Weight Reduction</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of Participants who Achieve ≥10% Body Weight Reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve ≥15% Body Weight Reduction</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of Participants who Achieve ≥15% Body Weight Reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Waist Circumference</measure>
    <time_frame>Randomization, Week 52</time_frame>
    <description>Mean Change from Randomization in Waist Circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Body Weight</measure>
    <time_frame>Randomization, Week 52</time_frame>
    <description>Mean Change from Randomization in Body Weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Body Mass Index (BMI)</measure>
    <time_frame>Randomization, Week 52</time_frame>
    <description>Mean Change from Randomization in BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Randomization, Week 52</time_frame>
    <description>Mean Change from Randomization in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Fasting Glucose (FSG)</measure>
    <time_frame>Randomization, Week 52</time_frame>
    <description>Mean Change from Randomization in FSG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Short-Form-36 Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score</measure>
    <time_frame>Randomization, Week 52</time_frame>
    <description>The SF-36v2 acute form, 1-week recall assesses participants' health-related quality of life (HRQoL) on 8 domains; 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning 7) limitations in usual role due to emotional problems; and 8) general mental health. Domain scores are norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10, with higher scores indicating better levels of function and/or better health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score</measure>
    <time_frame>Randomization, Week 52</time_frame>
    <description>The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5 item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. Individual composite scale scores and a total score can be computed and are presented on a scale of 0 to 100, with higher scores indicating better function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Randomization, Week 52</time_frame>
    <description>Mean Change from Randomization in DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Systolic Blood Pressure (SBP)</measure>
    <time_frame>Randomization, Week 52</time_frame>
    <description>Mean Change from Randomization in SBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Total Cholesterol</measure>
    <time_frame>Randomization, Week 52</time_frame>
    <description>Mean Change from Randomization in Total Cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in High Density Lipoprotein (HDL) Cholesterol</measure>
    <time_frame>Randomization, Week 52</time_frame>
    <description>Mean Change from Randomization in HDL Cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Low Density Lipoprotein (LDL) Cholesterol</measure>
    <time_frame>Randomization, Week 52</time_frame>
    <description>Mean Change from Randomization in LDL Cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Very Low Density Lipoprotein (VLDL) Cholesterol</measure>
    <time_frame>Randomization, Week 52</time_frame>
    <description>Mean Change from Randomization in VLDL Cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Triglycerides</measure>
    <time_frame>Randomization, Week 52</time_frame>
    <description>Mean Change from Randomization in Triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Free Fatty Acids</measure>
    <time_frame>Randomization, Week 52</time_frame>
    <description>Mean Change from Randomization in Free Fatty Acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Fasting Insulin</measure>
    <time_frame>Randomization, Week 52</time_frame>
    <description>Mean Change from Randomization in Fasting Insulin</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <condition>Metabolism and Nutrition Disorder</condition>
  <arm_group>
    <arm_group_label>Tirzepatide Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tirzepatide administered subcutaneously (SC) once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirzepatide Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tirzepatide administered SC once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo administered SC once a week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirzepatide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Tirzepatide Dose 1</arm_group_label>
    <arm_group_label>Tirzepatide Dose 2</arm_group_label>
    <other_name>LY3298176</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a BMI ≥28 kilogram/square meter (kg/m²), or ≥24 kg/m² and previous diagnosis with&#xD;
             at least one of the following comorbidities: hypertension, dyslipidemia, obstructive&#xD;
             sleep apnea, cardiovascular disease&#xD;
&#xD;
          -  Have a history of at least one self-reported unsuccessful dietary effort to lose body&#xD;
             weight&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have Diabetes Mellitus&#xD;
&#xD;
          -  Have a self-reported change in body weight &gt;5 kg within 3 months prior to screening&#xD;
&#xD;
          -  Have obesity induced by other endocrinological disorders&#xD;
&#xD;
          -  Have had a history of chronic or acute pancreatitis&#xD;
&#xD;
          -  Have a history of significant active or unstable Major Depressive Disorder (MDD) or&#xD;
             other severe psychiatric disorder within the last 2 years&#xD;
&#xD;
          -  Have any lifetime history of a suicide attempt&#xD;
&#xD;
          -  Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple&#xD;
             endocrine neoplasia syndrome type 2 (MEN-2)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559)</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tsinghua Changgung Hospital</name>
      <address>
        <city>Changping</city>
        <state>Beijing</state>
        <zip>102202</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13683685711</phone>
    </contact>
    <investigator>
      <last_name>Jianzhong Xiao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>862389012890</phone>
    </contact>
    <investigator>
      <last_name>Qifu Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhujiang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510280</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13602759769</phone>
    </contact>
    <investigator>
      <last_name>Chen Hong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen Second People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13602586681</phone>
    </contact>
    <investigator>
      <last_name>Dewen Yan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Qinhuangdao</name>
      <address>
        <city>Qinhuangdao Shi</city>
        <state>Hebei</state>
        <zip>066000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>15903366689</phone>
    </contact>
    <investigator>
      <last_name>Bowei Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fourth Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>18903602198</phone>
    </contact>
    <investigator>
      <last_name>Zhifeng Cheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of Science &amp;Technology</name>
      <address>
        <city>Luoyang Shi</city>
        <state>Henan</state>
        <zip>471003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13653880139</phone>
    </contact>
    <investigator>
      <last_name>Hongwei Jiang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>15838123695</phone>
    </contact>
    <investigator>
      <last_name>Qingju Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanhua University</name>
      <address>
        <city>Hengyang</city>
        <state>Hunan</state>
        <zip>421001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13974703153</phone>
    </contact>
    <investigator>
      <last_name>Xinhua Xiao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changzhou No.2 People's Hospital</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <zip>213000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>86 13616125500</phone>
    </contact>
    <investigator>
      <last_name>Xinhua Ye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>18951762690</phone>
    </contact>
    <investigator>
      <last_name>Yi Bing LU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing Medical University - Nanjing Jiangning Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>211100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13851502586</phone>
    </contact>
    <investigator>
      <last_name>Kun Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Nantong University</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <zip>226001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>15851207860</phone>
    </contact>
    <investigator>
      <last_name>Yunjuan Gu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuxi People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0510-82700775</phone>
    </contact>
    <investigator>
      <last_name>Lan Xu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13674315020</phone>
    </contact>
    <investigator>
      <last_name>Hanqing Cai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siping Central People's Hospital</name>
      <address>
        <city>Siping</city>
        <state>Jilin</state>
        <zip>136000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>18604343998</phone>
    </contact>
    <investigator>
      <last_name>Li Sun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jinan Central Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>15318816292</phone>
    </contact>
    <investigator>
      <last_name>Shuguang Pang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>8613651913857</phone>
    </contact>
    <investigator>
      <last_name>Xiaoying li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huadong Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>18621831253</phone>
    </contact>
    <investigator>
      <last_name>Jiao Sun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+86 13818808324</phone>
    </contact>
    <investigator>
      <last_name>Feng Tao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qingpu Branch of Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201700</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13681622338</phone>
    </contact>
    <investigator>
      <last_name>Min Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Medical University</name>
      <address>
        <city>XI 'an</city>
        <state>Shanxi</state>
        <zip>710077</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13892879939</phone>
    </contact>
    <investigator>
      <last_name>Ya LI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>18980605861</phone>
    </contact>
    <investigator>
      <last_name>Huiwen Tan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>18322017516</phone>
    </contact>
    <investigator>
      <last_name>Ming LIU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Hangzhou</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13858006098</phone>
    </contact>
    <investigator>
      <last_name>Lizhen Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huzhou Central Hospital</name>
      <address>
        <city>Huzhou</city>
        <state>Zhejiang</state>
        <zip>313000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13567288210</phone>
    </contact>
    <investigator>
      <last_name>Jianping Yao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ningbo First Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13780008400</phone>
    </contact>
    <investigator>
      <last_name>Jialin Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Chao Yang Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>(010)8523-1000</phone>
    </contact>
    <investigator>
      <last_name>Guang Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fifth People's Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <zip>200240</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>18918168586</phone>
    </contact>
    <investigator>
      <last_name>Jun Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Minhang District Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>201199</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>18918169177</phone>
    </contact>
    <investigator>
      <last_name>Xiaofang Fan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 15, 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tirzepatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

